help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, L. Y.
Right arrow Articles by Li, W. X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, L. Y.
Right arrow Articles by Li, W. X.

Endocrinology, Vol 134, 2431-2437, Copyright © 1994 by Endocrine Society

ARTICLES

Regulation of human chorionic gonadotropin secretion and messenger ribonucleic acid levels by follistatin in the NUCC-3 choriocarcinoma cell line

LY Shi, ZW Zhang and WX Li
Department of Physiology, Beijing Medical University, China.

In this study, the NUCC-3 choriocarcinoma cell line was used as an in vitro placental cell model to investigate the effects of follistatin on basal and GnRH-stimulated hCG secretion and/or its subunit mRNA levels. Follistatin (1.5-100 ng/ml; 48 h) alone did not affect basal hCG secretion or its subunit mRNA levels. GnRH increased hCG secretion and hCG beta-subunit mRNA levels in a dose-dependent manner, with maximal effects (2.37- and 2.4-fold increases, respectively) at a dose of 10(- 8) M after 24 h of culture (P < 0.001). The time-course study showed that the increase in hCG secretion induced by GnRH occurred between 6- 48 h after treatment. Follistatin (6-100 ng/ml; 48 h) significantly suppressed GnRH-stimulated hCG secretion and hCG alpha- and beta- subunit mRNA levels, with maximal suppression of 73.1%, 106.9%, and 129.1%, respectively (P < 0.001). In addition, follistatin (25 ng/ml) inhibited hCG secretion in response to phorbol 12-myristate 13-acetate (100 nM) by 90.3%. However, follistatin had no effect on hCG secretion evoked by forskolin (10 microM), and no change in hCG secretion was observed after treatment with a calcium ionophore (A23187; 10 microM) alone or in combination with follistatin. Furthermore, there was no significant difference in the half-lives of hCG alpha and -beta mRNA induced by GnRH alone compared with those induced by GnRH plus follistatin (P > 0.1), indicating that follistatin did not affect the stability of hCG alpha and -beta mRNA. Our data suggest that follistatin inhibits GnRH-stimulated hCG secretion as well as hCG alpha- and beta-subunit mRNA levels in the NUCC-3 choriocarcinoma cell line by decreasing the rate of transcription through the second messenger transduction system-protein kinase-C, rather than by affecting the stability of mRNA. These findings indicate that follistatin may play an important role in the regulation of hCG production in the placenta during pregnancy.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society